Literature DB >> 22265028

Immuno-microbiota cross and talk: the new paradigm of metabolic diseases.

Rémy Burcelin1, Lucile Garidou, Céline Pomié.   

Abstract

Over the last decades the rising occurrence of metabolic diseases throughout the world points to the failure of preventive and therapeutic strategies and of the corresponding molecular and physiological concepts. Therefore, a new paradigm needs to be elucidated. Very recently the intimate cross talk of the intestinal microbiota with the host immune system has opened new avenues. The large diversity of the intestinal microbes' genome, i.e. the metagenome, and the extreme plasticity of the immune system provide a unique balance which, when finely tuned, maintains a steady homeostasis. The discovery that a new microbiota repertoire is one of the causes responsible for the onset of metabolic disease suggests that the relationship with the immune system is impaired. Therefore, we here review the recent arguments that support the view that an alteration in the microbiota to host immune system balance leads to an increased translocation of bacterial antigens towards metabolically active tissues, and could result in a chronic inflammatory state and consequently impaired metabolic functions such as insulin resistance, hepatic fat deposition, insulin unresponsiveness, and excessive adipose tissue development. This imbalance could be at the onset of metabolic disease, and therefore the early treatment of the microbiota dysbiosis or immunomodulatory strategies should prevent and slow down the epidemic of metabolic diseases and hence the corresponding lethal cardiovascular consequences. Copyright Â
© 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22265028     DOI: 10.1016/j.smim.2011.11.011

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  49 in total

1.  Obesity and Metabolic Disease After Childhood Cancer.

Authors:  Dana Barnea; Nirupa Raghunathan; Danielle Novetsky Friedman; Emily S Tonorezos
Journal:  Oncology (Williston Park)       Date:  2015-11       Impact factor: 2.990

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men.

Authors:  Anne Salonen; Leo Lahti; Jarkko Salojärvi; Grietje Holtrop; Katri Korpela; Sylvia H Duncan; Priya Date; Freda Farquharson; Alexandra M Johnstone; Gerald E Lobley; Petra Louis; Harry J Flint; Willem M de Vos
Journal:  ISME J       Date:  2014-04-24       Impact factor: 10.302

Review 4.  RORγt, a multitask nuclear receptor at mucosal surfaces.

Authors:  G Eberl
Journal:  Mucosal Immunol       Date:  2016-10-05       Impact factor: 7.313

5.  Sleeve Gastrectomy Alters Intestinal Permeability in Diet-Induced Obese Mice.

Authors:  Claire Blanchard; François Moreau; Julien Chevalier; Audrey Ayer; Damien Garcon; Lucie Arnaud; Jean-Paul Pais de Barros; Thomas Gautier; Michel Neunlist; Bertrand Cariou; Cédric Le May
Journal:  Obes Surg       Date:  2017-10       Impact factor: 4.129

Review 6.  The science of fatty acids and inflammation.

Authors:  Kevin L Fritsche
Journal:  Adv Nutr       Date:  2015-05-15       Impact factor: 8.701

Review 7.  The price of immunity.

Authors:  Romina S Goldszmid; Giorgio Trinchieri
Journal:  Nat Immunol       Date:  2012-09-18       Impact factor: 25.606

Review 8.  Immunity by equilibrium.

Authors:  Gérard Eberl
Journal:  Nat Rev Immunol       Date:  2016-07-11       Impact factor: 53.106

Review 9.  Diabetes mellitus and inflammation.

Authors:  Eric Lontchi-Yimagou; Eugene Sobngwi; Tandi E Matsha; Andre Pascal Kengne
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 10.  Linking the Microbiota, Chronic Disease, and the Immune System.

Authors:  Timothy W Hand; Ivan Vujkovic-Cvijin; Vanessa K Ridaura; Yasmine Belkaid
Journal:  Trends Endocrinol Metab       Date:  2016-09-10       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.